Tyra Biosciences (NASDAQ:TYRA) Announces Earnings Results

Tyra Biosciences (NASDAQ:TYRA) posted its quarterly earnings data on Tuesday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04), Zacks reports.

Tyra Biosciences Trading Up 4.1%

Shares of NASDAQ:TYRA traded up $1.05 during midday trading on Thursday, hitting $26.76. The stock had a trading volume of 479,827 shares, compared to its average volume of 919,576. The company has a market capitalization of $1.59 billion, a PE ratio of -11.16 and a beta of 0.77. The stock has a 50 day moving average price of $30.30 and a two-hundred day moving average price of $32.71. Tyra Biosciences has a 1 year low of $9.96 and a 1 year high of $40.65.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TYRA shares. JonesTrading began coverage on Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Tyra Biosciences in a research note on Thursday, May 14th. Guggenheim assumed coverage on Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective for the company. Wolfe Research initiated coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.90.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in Tyra Biosciences by 2.0% in the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock valued at $753,000 after buying an additional 562 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Tyra Biosciences by 5.0% during the 4th quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after acquiring an additional 725 shares during the period. Virtus Investment Advisers LLC boosted its stake in shares of Tyra Biosciences by 6.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock worth $309,000 after acquiring an additional 741 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Tyra Biosciences by 5.8% during the 4th quarter. Deutsche Bank AG now owns 16,377 shares of the company’s stock worth $431,000 after acquiring an additional 894 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Tyra Biosciences by 12.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,432 shares of the company’s stock worth $380,000 after acquiring an additional 1,631 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.